Fusion protein delivery system and uses thereof

Details Fusion protein delivery system and uses thereof Fusion protein delivery system and uses thereof

2007-08-21

2007-08-21

Guzo, David (Department: 1636)

Chemistry: molecular biology and microbiology

Process of mutation, cell fusion, or genetic modification

Introduction of a polynucleotide molecule into or...

C435S320100, C435S456000, C536S023100, C536S023200, C536S023400, C536S023700, C536S023720, C536S024100

Reexamination Certificate

active

10245475

ABSTRACT:
The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.

REFERENCES:
patent: 5175099 (1992-12-01), Wills
patent: 5378806 (1995-01-01), Willis
patent: 5665577 (1997-09-01), Sodroski et al.
patent: 5861161 (1999-01-01), Cohen et al.
patent: 5981276 (1999-11-01), Sodroski et al.
patent: 6043081 (2000-03-01), Cohen et al.
patent: 6365150 (2002-04-01), Leboulch et al.
patent: 6602705 (2003-08-01), Barnett et al.
patent: 275259 (1990-01-01), None
patent: 356021 (1990-02-01), None
patent: WO90/15875 (1990-12-01), None
patent: WO92/00987 (1992-01-01), None
patent: WO93/24632 (1993-09-01), None
patent: WO93/25235 (1993-12-01), None
patent: WO94/17825 (1994-08-01), None
patent: WO95/16705 (1995-06-01), None
patent: WO95/26361 (1995-10-01), None
patent: WO96/07741 (1996-03-01), None
patent: WO96/11696 (1996-04-01), None
patent: WO96/32494 (1996-10-01), None
patent: WO97/36481 (1997-10-01), None
patent: WO99/58701 (1999-11-01), None
patent: WO 00/39302 (2000-07-01), None
Yu et al., J. Virol., 1998, vol. 72, No. 4, pp. 3412-3417.
Banerjee et al., Biochimica et Biophysica Acta, 2000, vol. 1480, pp. 1-5.
Groth et al., J. Mol. Biol., 2004, vol. 335, pp. 667-678.
Daboussi, Genetica, 1997, vol. 100, pp. 253-260.
Bennett, Journal of Antimicrobial Chemotherapy, 1999, vol. 43, pp. 1-4.
Kempkin et al., BioEssays, 1998, vol. 20, pp. 652-659.
Zhu et al., 2004, J. Virol., vol. 78, No. 10, pp. 5045-5055.
Akari, et al., “Biological Characterization Of Human Immunodeficiency Virus Type 1 and 2 Mutants In Human Peripheral Blood Mononuclear Cells,”Arch. Virol. 123:157-167 (1992).
Alton, et al., “Nucleotide Sequence Analysis of the Chloramphenicol Resistance Transposon Tn9,”Nature, 282:864-869 (1979).
Ansari, L., et al., “Expression of Human Immunodeficiency Virus Type 1 Reverse Transcriptase in trans during Virion Release and after Infection,”J. Virol. 70:3870-3875 (1996).
Ansari-Lari, et al., “Analysis of Human Immunodeficiency Virus Type 1 Integrase Mutant,”Virology211:332-335 (1995).
Balotta, et al., “Antisense Phosphorothioate Oligodeoxynucleotides Targeted to the vpr Gene Inhibit Human Immunodeficiency Virus Type I Replication in Primary Human Macrophages,”J. Virol. 67(7): 4409-4414 (Jul. 1993).
Bukovsky, et al., “Lack of Integrase Can Markedly Affect Human Immunodeficiency Virus Type 1 Particle Production in Presence of an Active Viral Protease,”J. Virol. 70:6820-6725 (1996).
Charneau, et al., “HIV-1 Reverse Transcription: A Termination Step at the Center of the Genome,”J. Mol. Biol. 241:651-662 (1994).
Cohen, et al., “Human Immunodeficiency Virus vpr Product Is a Virion-Associated Regulatory Protein,”J. Virol. 64(6): 3097-3099 (Jun. 1990).
Cohen, et al., “Identification of HIV-1 vpr Product and Function,”J. Acq. Immune Def. Synd. 3:11-18 (1990).
Dedera, et al., “Viral Protein R of Human Immunodeficiency Virus Types 1 and 2 Is Dispensable for Replication and Cytopathogenicity in Lymphoid Cells,”J. Virol. 63(7):3205-3208 (Jul. 1989).
Derosiers. “HIV with Multiple Gene Deletions as a Live Attenuated Vaccine for AIDS,”AIDS Research and Human Retroviruses, 8(3):411-421 (Nov. 3, 1992).
Di Marzio, et al., “Mutational Analysis of Cell Cycle Arrest, Nuclear Localization, and Virion Packaging of Human Immunodeficiency Virus Type 1 Vpr,”J. Virol. 69(12):7909-7916 (Dec. 1995).
Engelman, et al., “Multiple Effects of Mutations in Human Immunodeficiency Virus Type 1 Integrase on Viral Replication,”J. Virol. 69:2729-2736 (1995).
Finer, et al., “kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes,”Blood83:43-50 (1994).
Fletcher, et al., “Complementation of Integrase Function in HIV-1 Virons,” Fourth Conference on Retroviruses and Opportunistic Infections, Abstract No. 394 (Jan. 22, 1997).
Fletcher, et al., “Complementation of Integrase Function in HIV-1 Virons,”The EMBO Journal16(16):5123-5138 (1997).
Fletcher, et al., “Complementation of Integrase Function in HIV-1 Virons,” Third Conference on Retroviruses and Opportunistic Infections (Jan. 28, 1996).
George, et al., “Current Methods in Sequence Comparison and Analysis,”Macromolecule Sequencing and Synthesis, Selected Methods and Applications127-149.
Gibbs, et al., Construction and In Vitro Properties of SIV MAC Mutants with Deletions in “Nonessential”Genes, AIDS Research and Human Retroviruses, 10(5):607-616 (Nov. 5, 1994).
Gottlinger, et al., “Effect of Mutations Affecting the p6 gag Protein on Human Immunodeficiency Virus Particle Release,”Proc. Natl. Acad. Sci. 88:3195-3199 (Apr. 1991).
Guyader, et al., “VPX Mutants Of HIV-2 Are Infectious In Established Cell Lines but Display a Severe Defect in Peripheral Blood Lymphocytes,”The EMBO Journal8(4):1169-1175 (1989).
Hattori, et al., “The HIV-2 Vpr Gene is Essential for Macrophage Infections,” p. 309 (Abstract).
Hattori, et al., “The Human Immunodeficiency Virus Type 2 vpr Gene is Essential for Productive Infection of Human Macrophages,”Proc. Natl. Acad. Sci. USA87:8080-8084 (Oct. 1990).
He, et al., “Human Immunodeficiency Virus Type 1 Viral Protein R (Vpr) Arrests Cells in the G2 Phase of the Cell Cycle by Inhibiting p34cdc2 Activity,”J. Virol. 69(11):6705-6711 (Nov. 1995).
Heinzinger, et al., The Vpr Protein Of Human Immunodeficiency Virus Type 1 Influences Nuclear Localization Of Viral Nucleic Acids In Nondividing Host Cells,Proc. Natl. Acad. Sci. USA91:7311-7315 (Jul. 1994).
Hoch, et al., “vpr Deletion Mutant of Simian Immunodeficiency Virus Induces AIDS in Rhesus Monkeys,”J. Virol. 69(8):4807-4813 (Aug. 1995).
Horton, et al., “HIV-2 Viral Protein X Association with the Gag p27 Capsid Protein,”Virology199:453-457 (1994).
Hu, et al., “Analysis and Function Of Viral Protein X (VPX) of HIV-2”Virol. 173:624-630 (1989).
Huang, et al., “Mutational Analysis of the Murine AIDS-Defective Viral Genome Reveals a High Reversion Rate in Vivo and a Requirement for an Intact Pr60gag Protein for Efficient Induction of Disease,”Journal of Virology60-68 (Jan. 1995).
Huang, et al., “P6Gag Is Required for Particle Production from Full-Length Human Immunodeficiency Virus Type 1 Molecular Clones Expressing Protease,”Journal of Virology6810-6818 (Nov. 1995).
Hutchinson, et al., Mtagenesis at a Specific Position in a DNA Sequence,J. Biol. Chem. 253:6551.
Kappes, et al. “Human Immunodeficiency Virus Type 2 vpx Protein Augments Viral Infectivity,”Virology184:197-209 (1991).
Kappes, et al., “Identification of a Novel Retroviral Gene Unique to Human Immunodeficiency Virus Type 2 and Simian Immunodeficiency Virus SIV MAC,”J. Virol. 62(9):3501-3505 (Sep. 1988).
Kappes, et al., “Infectious Human Immunodeficiency Virus Type 1 Derived From Reverse Transcriptase (RT) and Integrase (IN) Minus ProvirusTransComplemented with VPR—Rt and—IN Fusion Protein,” Keystone Symposia (Apr. 8, 1997).
Kappes, et al., “Intracellular Transport and Virion Incorporation of vpx Requires Interaction with Other virus Type-Specific Components,”J. Virol. 193:222-233 (1993).
Kappes, et al., “The HIV Vpx and Vpr gene

Affiliated with

Also associated with

Rating

Fusion protein delivery system and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion protein delivery system and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion protein delivery system and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3831140